ストックスクリーナーアプリを入手
23.75
1.29%
-0.31
アフターアワーズ：
23.75
前日終値:
$24.06
開ける：
$23.95
24時間の取引高:
307.06K
Relative Volume:
0.37
時価総額：
$961.63M
収益：
$726.41M
当期純損益:
$7.03M
株価収益率:
151.18
EPS:
0.1571
ネットキャッシュフロー:
$136.66M
1週間 パフォーマンス:
+5.42%
1か月 パフォーマンス:
+2.11%
6か月 パフォーマンス:
+4.49%
1年 パフォーマンス:
-4.89%
1日の値動き範囲:
$23.69
$24.38
1週間の範囲:
$22.75
$24.38
52週間の値動き範囲:
$18.80
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
名前
Pacira Biosciences Inc
セクター
電話
650-242-8052
住所
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
23.75 | 963.25M | 726.41M | 7.03M | 136.66M | 0.1571 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Equal Weight |
| 2025-11-17 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-25 | アップグレード | Truist | Hold → Buy |
| 2025-01-30 | アップグレード | Truist | Sell → Hold |
| 2024-08-13 | ダウングレード | Truist | Buy → Sell |
| 2024-08-12 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2024-08-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-07 | 再開されました | JP Morgan | Overweight |
| 2023-12-20 | 開始されました | Raymond James | Outperform |
| 2023-08-03 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 再開されました | Wedbush | Outperform |
| 2022-10-21 | 再開されました | Jefferies | Buy |
| 2022-01-03 | 再開されました | JP Morgan | Overweight |
| 2021-07-26 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 再開されました | JP Morgan | Neutral |
| 2021-04-09 | 開始されました | Berenberg | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2021-02-11 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 繰り返されました | Needham | Buy |
| 2020-05-27 | 開始されました | Guggenheim | Neutral |
| 2020-04-07 | 開始されました | Northland Capital | Outperform |
| 2020-03-20 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-24 | 開始されました | SunTrust | Buy |
| 2020-01-23 | 開始されました | SunTrust | Buy |
| 2019-11-06 | 開始されました | BTIG Research | Buy |
| 2019-06-11 | 開始されました | Barclays | Overweight |
| 2019-05-06 | アップグレード | Mizuho | Underperform → Neutral |
| 2019-05-02 | アップグレード | Stifel | Sell → Hold |
| 2019-02-01 | ダウングレード | Mizuho | Neutral → Underperform |
| 2018-08-06 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-03-21 | 繰り返されました | Mizuho | Neutral |
| 2018-02-16 | ダウングレード | Needham | Buy → Hold |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2018-01-04 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-01-03 | 開始されました | Leerink Partners | Mkt Perform |
すべてを表示
Pacira Biosciences Inc (PCRX) 最新ニュース
Pacira (PCRX) Data Highlights Cost Benefits and Opioid Reduction - GuruFocus
Pacira BioSciences, Inc. Presents Real-World Data On EXPAREL Showing Lower Total Healthcare Costs In Outpatient Total Hip And Knee Arthroplasty Procedures - marketscreener.com
Pacira (PCRX) Highlights Economic Benefits of Exparel in Orthope - GuruFocus
Hip replacement patients with back pain used fewer opioids with EXPAREL - Stock Titan
(PCRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Investment Recap: Can Pacira BioSciences Inc expand its profit marginsWeekly Trade Report & Risk Controlled Daily Plans - baoquankhu1.vn
PCRX.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Weekly Earnings: Is Pacira BioSciences Inc stock a falling knife or bargain buy2026 Outlook & Risk Managed Investment Strategies - baoquankhu1.vn
PCRX.O Technical Analysis & Stock Price Forecast - Intellectia AI
Dimensional Fund Advisors (NASDAQ: PCRX) reports 2.06M shares owned - Stock Titan
Pacira BioSciences, Inc. (PCRX) Stock Forecasts - Yahoo Finance
PCRX Should I Buy - Intellectia AI
PCRX.O PE Ratio & Valuation, Is PCRX.O Overvalued - Intellectia AI
PCRX News & Events - Intellectia AI
Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Pacira investors get live access to Needham healthcare event April 15 - Stock Titan
Pacira (PCRX) BioSciences well-positioned with genicular outcomes registry evidence - MSN
2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation | NDAQ:PCRX | Press Release - Stockhouse
PCRX Technical Analysis & Stock Price Forecast - Intellectia AI
PCRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
2026-04-02 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences, Inc. (PCRX) Stock forecasts - Yahoo Finance UK
Analysts Set Expectations for PCRX Q1 Earnings - MarketBeat
(PCRX) Risk Channels and Responsive Allocation - Stock Traders Daily
2026-03-31 | Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira (PCRX) BioSciences Well-Positioned With Genicular Outcomes Registry Evidence - Insider Monkey
Hennion & Walsh Asset Management Inc. Acquires 87,210 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences to Present Real-World Data on EXPAREL Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting - Bitget
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting - Ortho Spine News
Study data linked EXPAREL to lower knee and spine surgery costs - Stock Titan
2026-03-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences, Inc. $PCRX Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
Bull Run: Is Pacira BioSciences Inc impacted by rising ratesQuarterly Profit Report & Expert Curated Trade Ideas - baoquankhu1.vn
Vanguard amends Schedule 13G/A after internal realignment (PCRX) - stocktitan.net
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
2026-03-26 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences (NASDAQ:PCRX) Price Target Cut to $25.00 by Analysts at Barclays - MarketBeat
PCRX: Barclays Lowers Price Target to $25, Maintains Equal-Weigh - GuruFocus
2026-03-24 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira faces board fight as activist investor criticizes CEO pay, missed earnings - MSN
(PCRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Insider Sell: Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX) - gurufocus.com
Froimson Mark sells Pacira BioSciences (PCRX) shares for $10905 By Investing.com - Investing.com South Africa
Pacira BioSciences’ chief medical officer sells $74k in stock By Investing.com - Investing.com Australia
Insider Selling: Pacira BioSciences (NASDAQ:PCRX) Insider Sells 3,261 Shares of Stock - MarketBeat
Froimson Mark sells Pacira BioSciences (PCRX) shares for $10905 - Investing.com UK
Pacira Biosciences Inc (PCRX) 財務データ
収益
当期純利益
現金流量
EPS
1.06%
1.05%
大文字化:
|
ボリューム (24 時間):